Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Adv Hematol. 2012 Dec;3(6):341-54. doi: 10.1177/2040620712459746.

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Author information

  • 1Guy's and St Thomas's NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.

Abstract

Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.

KEYWORDS:

JAKafi; janus kinase 2; myelofibrosis; myeloproliferative neoplasm; ruxolitinib

PMID:
23606937
[PubMed]
PMCID:
PMC3627327
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk